Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey.

Waldschmitt C, Vogel F, Pfuhlmann B, Hiemke C.

Pharmacopsychiatry. 2009 Sep;42(5):189-93. doi: 10.1055/s-0029-1220890. Epub 2009 Sep 1.

PMID:
19724981
2.

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.

Mehler-Wex C, Kölch M, Kirchheiner J, Antony G, Fegert JM, Gerlach M.

Child Adolesc Psychiatry Ment Health. 2009 Apr 9;3(1):14. doi: 10.1186/1753-2000-3-14.

3.

The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

Jin Y, Pollock BG, Frank E, Florian J, Kirshner M, Fagiolini A, Kupfer DJ, Gastonguay MR, Kepple G, Feng Y, Bies RR.

J Clin Pharmacol. 2009 Feb;49(2):176-84. doi: 10.1177/0091270008327538.

4.

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Hiemke C.

Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:21-7. doi: 10.1007/s00406-007-1005-y. Review.

PMID:
18344046
5.

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J.

JAMA. 2008 Feb 27;299(8):901-13. doi: 10.1001/jama.299.8.901.

6.

Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.

Birmaher B, Brent D; AACAP Work Group on Quality Issues, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J.

J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1503-26.

PMID:
18049300
8.

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.

Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA.

JAMA. 2007 Apr 18;297(15):1683-96.

PMID:
17440145
9.

Time course of response to paroxetine: influence of plasma level.

Gex-Fabry M, Gervasoni N, Eap CB, Aubry JM, Bondolfi G, Bertschy G.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):892-900. Epub 2007 Feb 15.

PMID:
17395353
10.
11.

Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study.

Daviss WB, Perel JM, Brent DA, Axelson DA, Rudolph GR, Gilchrist R, Nuss S, Birmaher B.

Ther Drug Monit. 2006 Apr;28(2):190-8.

PMID:
16628130
12.

The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression.

Findling RL, McNamara NK, Stansbrey RJ, Feeny NC, Young CM, Peric FV, Youngstrom EA.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):131-45. Review.

PMID:
16553534
13.
14.

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S.

Am J Psychiatry. 2004 May;161(5):826-35.

PMID:
15121647
15.

Time course of clinical response to venlafaxine: relevance of plasma level and chirality.

Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G.

Eur J Clin Pharmacol. 2004 Feb;59(12):883-91. Epub 2003 Dec 24.

PMID:
14704834
16.

Considerations in analyzing single-trough concentrations using mixed-effects modeling.

Booth BP, Gobburu JV.

J Clin Pharmacol. 2003 Dec;43(12):1307-15.

PMID:
14615466
17.

Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.

Charlier C, Pinto E, Ansseau M, Plomteux G.

J Psychopharmacol. 2002 Dec;16(4):369-72.

PMID:
12503838
18.

Sertraline pharmacokinetics and dynamics in adolescents.

Axelson DA, Perel JM, Birmaher B, Rudolph GR, Nuss S, Bridge J, Brent DA.

J Am Acad Child Adolesc Psychiatry. 2002 Sep;41(9):1037-44.

PMID:
12218424
19.

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.

Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM.

Am J Psychiatry. 1997 Jul;154(7):963-9.

PMID:
9210747
20.

Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection.

Foglia JP, Sorisio D, Kirshner M, Pollock BG.

J Chromatogr B Biomed Sci Appl. 1997 May 23;693(1):147-51.

PMID:
9200528

Supplemental Content

Support Center